USPTO trademark

DISRUPTIDE

Under examinationUSPTOWord markClass 1Class 42

"DISRUPTIDE" is a word mark owned by Rime Therapeutics Inc., filed at the USPTO on May 20, 2026. It is under examination and covers classes 1 and 42.

Get this data via the API
Official USPTO record
DISRUPTIDE trademark as filed
As filed with the USPTO
Status
Under examination
Since September 17, 2026
Filed
May 20, 2026
Registered
Not yet
Expires
Not recorded
Application no.
99834893
Registration no.
Not yet
Office
USPTO
United States Patent and Trademark Office
Mark type
Word mark
2 classes
Ownership

Who owns DISRUPTIDE

The owner and representative on file with the office.

Owner

Rime Therapeutics Inc.

Montréal, Canada

Representative

Karen K. Won

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C

Goods and services

What the mark covers

The products and services DISRUPTIDE is filed for, grouped by Nice class.

  • chemical preparations and reagents, namely, peptide sequences and peptide probes for use in drug discovery and development; AI-designed peptide probes for use in drug discovery and development; live-cell functional assays and drug screen assays involving engineered peptide probes, for research purposes; engineered peptide probes for live-cell phenotypic screening, intracellular target identification and validation, generation of molecular chemical profiles of function hits at defined target sites, and peptide-based drug discovery and development; genetically-deliverable peptide sequences and peptide probes for preserving peptide conformation, minimizing steric interference, and enhancing peptide intracellular stability

  • Drug and drug target discovery services; Design, development, and engineering of peptide sequences and peptide probes for use in drug discovery and development; Medical scientific research, analysis, and testing, namely, using engineered peptide probes in live-cell phenotypic screening, intracellular target identification and validation, generation of molecular chemical profiles of function hits at defined target sites, and peptide-based drug discovery and development; Using AI-designed peptide probes to conduct research, testing, and analysis of peptide-target pairs as molecular blueprints for developing small molecule inhibitors; Providing medical scientific information, advisory, and consultancy services in the fields of peptides, peptide-based drug discovery and development, and phenotypic drug screening

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. Notification of non-final action e-mailed
  2. Non-final action e-mailed
  3. Non-final action written
  4. Assigned to examiner
  5. New application office supplied data entered
  6. Application filing receipt mailed
  7. New application entered
FAQ

About DISRUPTIDE

Who owns the trademark "DISRUPTIDE"?

The USPTO trademark "DISRUPTIDE" (application 99834893) is owned by Rime Therapeutics Inc.

What is the status of "DISRUPTIDE"?

Its status at the USPTO is: under examination.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull DISRUPTIDE and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_019e4e1b-5ba2-759a-9436-4f78b2f47b03
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_019e4e1b-5ba2-759a-9436-4f78b2f47b03",
  "object": "trademark",
  "mark_text": "DISRUPTIDE",
  "status": {
    "primary": "pending",
    "stage": "examining"
  },
  "office_code": "US",
  "application_number": "99834893",
  "filing_date": "2026-05-20",
  "nice_classes": [
    1,
    42
  ],
  "owners": [
    {
      "name": "Rime Therapeutics Inc.",
      "entity_id": null
    }
  ]
}